Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 9/20 | 0.55 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.43 |
| ▸ | FUCA1 | P04066 | 4/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | GLB1 | P16278 | 1/20 | 0.40 |
| ▸ | GANAB | Q14697 | 1/20 | 0.35 |
| ▸ | PYGL | P06737 | 1/20 | 0.35 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL955176 | 1.00 | GBA1 (0.55) | GBA1MAN1B1FUCA1GLAGAA | |
| SCHEMBL23775007 | 0.80 | GBA1 (0.53) | GBA1MAN1B1FUCA1GLAGAA | |
| SCHEMBL24920095 | 0.77 | GBA1 (0.45) | GBA1MAN1B1GAAGLB1GBA2 | |
| SCHEMBL7404065 | 0.73 | — | — | |
| SCHEMBL22768152 | 0.73 | — | — | |
| SCHEMBL17037474 | 0.73 | — | — | |
| SCHEMBL6042278 | 0.72 | GBA1 (0.39) | GBA1 | |
| SCHEMBL7405332 | 0.71 | — | — | |
| SCHEMBL6857546 | 0.71 | GBA1 (1.00) | GBA1FUCA1GLAGAAGLB1 | |
| SCHEMBL6857545 | 0.71 | GBA1 (1.00) | GBA1FUCA1GLAGAAGLB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454263-B1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | ALBERT EINSTEIN COLLEGE MEDICINE INC (US) | 2018-06-13 | — | — | EP | disclosed |
| US-9957272-B2 | 3-hydroxypyrrolidine inhibitors of 5′-methylthioadenosine phosphorylase and nucleosidase | VICTORIA LINK LIMITED (NZ) | 2018-05-01 | — | — | US | disclosed |
| US-20170166573-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | VICTORIA LINK LIMITED (NZ) | 2017-06-15 | — | — | US | disclosed |
| US-9493465-B2 | 3-hydroxypyrrolidine inhibitors of 5′-methylthioadenosine phosphorylase and nucleosidase | VICTORIA LINK LIMITED (NZ) | 2016-11-15 | — | — | US | disclosed |
| US-20120157479-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | INDUSTRIAL RESEARCH LIMITED (NZ) | 2012-06-21 | — | — | US | disclosed |
| EP-2454263-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | The Albert Einstein College Of Medicine Of Yeshiva University (US) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011008110-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | ALBERT EINSTEIN COLLEGE OF YESHIVA UNIVERSITY (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157479-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | TYMP, MTAP, PNP | GBA1 318/4885MAN1B1 850/4885FUCA1 111/4885 |
| US-20170166573-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | TYMP, MTAP, PNP | GBA1 268/4885MAN1B1 798/4885FUCA1 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.